Results 61 to 70 of about 19,861 (100)

Discovery of a novel and potent KRAS^G12V-targeting peptide with antiproliferative activity against colorectal cancer cells. [PDF]

J Enzyme Inhib Med Chem
Zhang H, Yang S, Wang Y, Niu MM, She J.
europepmc   +1 more source

The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium. [PDF]

Oncogene
Yang MH, Sheth S, Shui B, Grabski IN, Park SS, Cobo A, Irizarri R, Heymach JV, Dow LE, Haigis KM.   +9 more
europepmc   +1 more source

Autophagy in Ovarian Cancer, an Opportunity or an Additional Threat? [PDF]

Int J Mol Sci
Zoń A, Bednarek IA.
europepmc   +1 more source

Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases. [PDF]

Arterioscler Thromb Vasc Biol
Mastrogiacomo DM, Price A, Fu Y, Banerjee R, Knauer LA, Li K, Yang Y, Davis GE, Dellinger MT, Scallan JP.   +9 more
europepmc   +1 more source

G0 or no-G0: phosphatase control of quiescence and cell cycle entry. [PDF]

Biochem Soc Trans
Robinson EA, Barr AR.
europepmc   +1 more source

Crosstalk between circRNAs and the MAPK signaling pathway in cancer progression. [PDF]

Discov Oncol
Zahedi M, Maghrebi-Ghojogh E, Ahangari F, Zamani Sani M, Mafi A, Hushmandi K, Olianasab SA, Daneshi S, Alimohammadi M, Khoshnazar SM, Farahani N, Hashemi M, Taheriazam A.   +12 more
europepmc   +1 more source

Combining network pharmacology and experimental validation to study the action and mechanism of brusatol against lung adenocarcinoma. [PDF]

Sci Rep
Jin X, Yang S, Pan D, Jin B, Zhang Y, Yang C.   +5 more
europepmc   +1 more source

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation. [PDF]

Cochrane Database Syst Rev
Noordhof A, Asmara OD, de Jong K, Gijtenbeek RG, Huitema YM, van Vollenhoven FH, Venmans BJ, Hendriks L, van Geffen WH.   +8 more
europepmc   +1 more source

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non-Squamous Non-Small Cell Lung Cancer (Non-SQ NSCLC) Patients in Queensland, Australia From 2014-2023. [PDF]

Thorac Cancer
Niranjan N, Guan T, Niranjan N, Taherian Fard A, Youlden DR, Mason R, Chan BA, Sanmugarajah J.   +7 more
europepmc   +1 more source

Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis. [PDF]

Oncologist
Khamis MM, Lapari MS, Alkharabsheh O, Baral MR, Sahin IH, Archwamety A, Firwana B, Patel GK, Singh A, Al Diffalha S, Manne U, Khushman M.   +11 more
europepmc   +1 more source